New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies.

ABSTRACT: Myasthenia gravis (MG) is a chronic autoimmune disease for which multiple immunomodulatory therapies are available. Nevertheless, MG has a significant impact on patient quality of life. In recent years, experts' main efforts have focused on optimizing treatment strategies, since disease burden is considerably affected by their safety and tolerability profiles, especially in patients with refractory phenotypes. This article aims to offer neurologists caring for MG patients an overview of the most innovative targeted drugs specifically designed for this disease and summarizes the recent literature and more recent evidence on agents targeting B cells and plasmablasts, complement inhibitors, and neonatal fragment crystallizable receptor (FcRn) antagonists. Positive clinical trial results have

SUBMITTER: Sanchez-Tejerina D 

PROVIDER: S-EPMC9658349 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature